Dr. Yiqing Xu, MD, PhD

Dr. Xu practices at Maimonides Cancer Center in Brooklyn, New York.

Dr. Xu's NPI, 1245292333, was assigned on April 4, 2006. Dr. Xu graduated from JS Weill Medical College, Cornell University in 1988. Dr. Xu holds New York license 240969.

Dr. Xu's primary practice is Maimonides Cancer Center, at 6300 8th Ave, Brooklyn, NY 11220 in Kings County. The practice phone is (718) 283-8773.

Dr. Xu's primary practice is Maimonides Cancer Center in Brooklyn, New York. Dr. Xu is also affiliated with Maimonides Medical Center. The medical group on file is Maimonides Medical Center. Dmand AI also links Dr. Xu to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Xu practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Xu's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Xu's licenses on file in 2 states: New York and Ohio.

CMS data shows 515 Medicare services from Dr. Xu across 5 procedure codes in 2024, for 145 Medicare patients. Medicare paid $41,987 for them.

CMS counts 145 Medicare patients who saw Dr. Xu in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 62% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Xu's median patient age at 71, with 66% women.

In 2024, Dr. Xu wrote 1,841 Medicare Part D claims for 192 patients. 82% of them were for generic drugs. CMS names the drug for 1,609 of them, across 41 drugs with 11 or more claims each, at $3,471,731 in total drug cost. In 2023, CMS named 1,602 claims across 43 drugs.

Dr. Xu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 53 papers to Dr. Xu, published from 2012 to 2024. 2022 was the busiest year, with 4. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Asian. Dr. Xu has published most often in Opt Lett. Dr. Xu's most frequent co-authors are Yiwu Huang, MD, Vivek Kumar, MD and Sudhamshi Toom.

Dmand AI links Dr. Xu to 2 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Colorectal Neoplasms, Hereditary Nonpolyposis, Vaginal Neoplasms and DNA Repair-Deficiency Disorders. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 566 general payments to Dr. Xu from 51 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $15,470.

Dr. Xu graduated from JS Weill Medical College, Cornell University in 1988.